468 related articles for article (PubMed ID: 16761207)
21. [Role of the pathologist in the processing of adenocarcinoma of the stomach, oesophagogastric junction and lower third of the oesophagus].
Svrcek M; Fléjou JF
Ann Pathol; 2011 Dec; 31(6):419-26. PubMed ID: 22172114
[TBL] [Abstract][Full Text] [Related]
22. [Long-term survival after eso-gastrectomy for esophagogastric junction adenocarcinoma--prospective study].
Bîrlă R; Iosif C; Mocanu A; Gîndea C; Hoară P; Panaitescu E; Constantinoiu S
Chirurgia (Bucur); 2008; 103(6):635-42. PubMed ID: 19274907
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
[TBL] [Abstract][Full Text] [Related]
24. [Importance of neoadjuvant chemotherapy in gastrointestinal tumors. A new standard?].
Moosmann N; Boeck S; Heinemann V
Med Klin (Munich); 2007 Jul; 102(7):551-62; quiz 563-4. PubMed ID: 17634873
[No Abstract] [Full Text] [Related]
25. [Problematic results of a randomized study of neoadjuvant radiochemotherapy of operable esophageal carcinoma].
Fietkau R; Kundt G
Strahlenther Onkol; 2001 Jul; 177(7):372-3. PubMed ID: 11505624
[No Abstract] [Full Text] [Related]
26. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
27. [Adenocarcinoma of the Barrett esophagus. Apropos of 44 resected cases].
Lozac'h P; Topart P; Volant A
J Chir (Paris); 1997 Nov; 134(5-6):218-26. PubMed ID: 9772976
[No Abstract] [Full Text] [Related]
28. [Value of postoperative radiochemotherapy with 5-fluorouracil plus leucovorin in stage IB-IV M0 stomach carcinoma].
Hehr T; Adamek HE
Strahlenther Onkol; 2002 Mar; 178(3):164-6. PubMed ID: 11962195
[No Abstract] [Full Text] [Related]
29. [Current theraphy of oesophageal cancer].
Baumhoer D; Ramadori G
Z Gastroenterol; 2004 Feb; 42(2):171-4. PubMed ID: 14963791
[No Abstract] [Full Text] [Related]
30. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis.
Zhang CD; Zeng YJ; Li HW; Zhao ZM; Zhang JK; Dai DQ
Cancer Invest; 2013 Jul; 31(6):421-31. PubMed ID: 23758189
[TBL] [Abstract][Full Text] [Related]
32. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction.
Barbour AP; Rizk NP; Gerdes H; Bains MS; Rusch VW; Brennan MF; Coit DG
J Am Coll Surg; 2007 Oct; 205(4):593-601. PubMed ID: 17903735
[TBL] [Abstract][Full Text] [Related]
33. Combined modality therapy of gastric cancer.
Karpeh MS; Kelsen DP
Surg Oncol Clin N Am; 1997 Oct; 6(4):741-7. PubMed ID: 9309091
[TBL] [Abstract][Full Text] [Related]
34. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Elsaleh H; Farrell JJ; Crane CH
J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
[No Abstract] [Full Text] [Related]
35. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.
Lagarde SM; ten Kate FJ; Reitsma JB; Busch OR; van Lanschot JJ
J Clin Oncol; 2006 Sep; 24(26):4347-55. PubMed ID: 16963732
[TBL] [Abstract][Full Text] [Related]
36. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.
Leers JM; Ayazi S; Hagen JA; Terterov S; Klipfel N; Oezcelik A; Abate E; Lipham JC; DeMeester SR; Banki F; DeMeester TR
J Am Coll Surg; 2009 Apr; 208(4):553-6. PubMed ID: 19476789
[TBL] [Abstract][Full Text] [Related]
37. Innovative drugs and strategies in the treatment of upper gastrointestinal tract carcinomas.
Menges M; Hoehler T
Onkologie; 2004 Feb; 27(1):47-53. PubMed ID: 15007248
[TBL] [Abstract][Full Text] [Related]
38. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325
[TBL] [Abstract][Full Text] [Related]
39. [Principles of neoadjuvant therapy].
Lordick F
Chirurg; 2009 Nov; 80(11):1000-5. PubMed ID: 19812908
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials.
Fu T; Bu ZD; Li ZY; Zhang LH; Wu XJ; Wu AW; Shan F; Ji X; Dong QS; Ji JF
BMC Cancer; 2015 Apr; 15():322. PubMed ID: 25928286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
